Pharmather applies for provisional PatchPrint patent

Executive Summary

• Pharmather Holdings Ltd. has submitted a provisional patent application to the U.S. Patent and Trademark Office for "PatchPrint," an automated tabletop microneedle patch 3-D printer.
• The company is evolving from a microneedle patch developer into a broader solution provider, using PatchPrint to support its existing PharmaPatch programs (ketamine, psychedelics, GLP-1, therapeutic peptides) and expand into manufacturing systems and strategic commercial partnerships.
• Pharmather has initiated discussions with a medical-focused 3-D printer manufacturer to establish supply chain, engineering, and go-to-market pathways for PatchPrint systems.

Key Details

• Patent Filing: Submitted a provisional patent application (No. 64/015,408) titled "Automated Tabletop Microneedle Patch Printer with Integrated Demolding, Packaging and Multi-Product Cargo-Adaptive Processing."
• Technology Specifications: PatchPrint is an automated, compact, tabletop system that integrates dispensing, vacuum loading, accelerated drying, automated demoulding, and packaging in a single unit.
• Target Applications: The system is designed for deployment in pharmaceutical companies, hospitals, compounding pharmacies, and remote settings for medical countermeasures and vaccines. It supports programmable production for small-molecule drugs, proteins, dietary supplements, biologics, and peptides.
• Existing Programs Supported: The technology supports Pharmather's PharmaPatch programs for ketamine, psychedelic compounds, GLP-1, and therapeutic peptides.
• Commercialization Strategy: The company is focusing on commercialization, including:
  • Discussions with a medical-focused 3-D printer manufacturer for supply chain and manufacturing support.
  • Advancing peptide microneedle patches.
  • Developing branded wound care and dermatology products for wellness and cosmeceutical applications.
  • Pursuing development and commercial contracts with pharmaceutical/biotech companies, compounding pharmacies, consumer brands, and government agencies.
• Market Opportunities: Identified opportunities across therapeutics, consumer health, diagnostics, medical countermeasures, peptides, wound care, cosmeceuticals, vaccines, metabolic disorders (diabetes/obesity), and wellness products.

Notable Quotes

• "This patent filing is an exciting step in Pharmather's evolution into a microneedle patch platform company... With PatchPrint, we are expanding beyond our PharmaPatch product development efforts to build a business spanning manufacturing, formulations, proprietary products and strategic partnerships while also supporting and scaling our existing PharmaPatch programs." — Fabio Chianelli, CEO